Skip to content

CIK 0001556263

SYRS Syros Pharmaceuticals, Inc.

Insider trading from SEC Form 4. Last filing Dec 4, 2024. Close $0.00 on Oct 9, 2026, +300% from the 52-week low and -97% from the high.

Syros Pharmaceuticals, Inc. (SYRS) has 12 SEC Form 4 filings on file from 6 insiders, the latest filed on Dec 4, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

7 open-market trades have been scored at SYRS. The newest: Nancy A Simonian (director) sold $10k of stock on Dec 2, 2024, filed Dec 4, 2024, scored 50 (moderate). The largest of the 7 shown: Nancy A Simonian (director) sold $36k on Nov 25, 2024, scored 56 (moderate). 6 insiders sold within 14 days of each other around Dec 2, 2024.

SYRS closed at $0.00 on Oct 9, 2026, 300% above its 52-week low and 97% below its 52-week high.

19 Form 144 notices of planned sales are on file, the latest filed Mar 14, 2025.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company

Price and insider trades, last year

SYRSOct 9, 2026 · close 0.00

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Syros Pharmaceuticals, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
50ModerateNancy A Simonian
director
sell
$10k
37,070 shares
-90%-
56ModerateNancy A Simonian
director
sell
$36k
134,713 shares
-77%-
65NotableConley Chee
President & CEO
sell
$27k
134,797 shares
-100%-
62NotableJason Haas
Chief Financial Officer
sell
$29k
137,803 shares
-100%-
50ModerateGerald E Quirk
Chief Legal & Compliance Offic
sell
$10k
46,657 shares
-100%-
50ModerateDavid Roth
Chief Medical Officer
sell
$2,382
12,099 shares
-100%-
50ModerateKristin Stephens
Chief Development Officer
sell
$7,949
36,133 shares
-100%-

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
Mar 14, 2025 Fanucci Marsha
Director
9,333
0.03% of outstanding
$924Mar 14, 2025none
Mar 11, 2025 WIRTH PETER
Director
9,333
0.03% of outstanding
$2,008Mar 11, 2025none
Jan 16, 2025 Flagship Pioneering Fund VII, L.P.
Affiliate
1,135,308
4.23% of outstanding
$272kDec 27, 2024$466k
Dec 30, 2024 AKKARAJU SRINIVAS
Director
9,333
0.03% of outstanding
$2,306Dec 30, 2024none
Dec 27, 2024 Flagship Pioneering Fund VII, L.P.
Affiliate
1,331,624
4.96% of outstanding
$280kDec 27, 2024$203k
Dec 13, 2024 Flagship Pioneering Fund VII, L.P.
Affiliate
1,000,000
3.73% of outstanding
$230kDec 13, 2024none
Dec 13, 2024 Flagship VentureLabs IV LLC
Affiliate
21,333
0.08% of outstanding
$4,907Dec 13, 2024none
Dec 13, 2024 Flagship Ventures Fund IV, LP
Affiliate
216,590
0.81% of outstanding
$50kDec 13, 2024none
Dec 13, 2024 Flagship Ventures Fund IV-RX, LP
Affiliate
55,925
0.21% of outstanding
$13kDec 13, 2024none
Dec 10, 2024 Richard Young
Director
6,667
0.02% of outstanding
$1,533Dec 10, 2024none
Dec 2, 2024 Nancy Cole
Director
37,070
0.14% of outstanding
$10kDec 2, 2024none
Nov 25, 2024 Simonian Nancy A
Director
134,713
0.50% of outstanding
$27kNov 25, 2024none
Nov 19, 2024 Quirk Gerald E
Officer
46,657
0.17% of outstanding
$10kNov 19, 2024$6,509
Nov 18, 2024 Chee Conley
Officer
100,000
0.37% of outstanding
$26kNov 18, 2024$18k
Nov 18, 2024 Chee Conley
Officer
30,797
0.11% of outstanding
$6,139Nov 18, 2024$18k
Nov 18, 2024 JASON HAAS
Officer, Director
100,000
0.37% of outstanding
$20kNov 18, 2024none
Nov 18, 2024 Haas Jason
Officer
37,803
0.14% of outstanding
$8,669Nov 18, 2024$12k
Nov 18, 2024 Roth David
Officer
12,099
0.05% of outstanding
$2,382Nov 18, 2024$14k
Nov 18, 2024 Stephens Kristin
Officer
36,133
0.13% of outstanding
$7,949Nov 18, 2024$13k

Transactions

Every row filed, 21 in all.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Dec 2, 2024Nancy A Simonian
director
SOpen-market sale
Common Stock
-37,070$0.27$10k4,000Dec 4, 2024
Nov 25, 2024Nancy A Simonian
director
SOpen-market sale
Common Stock
-134,713$0.27$36k41,070Nov 27, 2024
Nov 19, 2024Gerald E Quirk
Chief Legal & Compliance Offic
SOpen-market sale
Common Stock
-46,657$0.22$10k0Nov 20, 2024
Nov 18, 2024Conley Chee
President & CEO
SOpen-market sale
Common Stock
-134,797$0.20$27k0Nov 20, 2024
Nov 18, 2024Jason Haas
Chief Financial Officer
SOpen-market sale
Common Stock
-137,803$0.21$29k0Nov 20, 2024
Nov 18, 2024David Roth
Chief Medical Officer
SOpen-market sale
Common Stock
-12,099$0.20$2,3820Nov 20, 2024
Nov 18, 2024Kristin Stephens
Chief Development Officer
SOpen-market sale
Common Stock
-36,133$0.22$7,9490Nov 20, 2024
Oct 31, 2024Jason Haas
Chief Financial Officer
MOption exercise
Common Stock10b5-1
+18,875--143,427Nov 4, 2024
Oct 31, 2024Kristin Stephens
Chief Development Officer
MOption exercise
Common Stock10b5-1
+17,000--42,237Nov 4, 2024
Oct 31, 2024Nancy A Simonian
director
MOption exercise
Common Stock
+40,125--175,783Nov 4, 2024
Oct 31, 2024David Roth
Chief Medical Officer
MOption exercise
Common Stock10b5-1
+18,875--18,875Nov 4, 2024
Oct 31, 2024Conley Chee
President & CEO
MOption exercise
Common Stock10b5-1
+17,000--139,504Nov 4, 2024
Oct 31, 2024Jason Haas
Chief Financial Officer
FTax withholding
Common Stock10b5-1
-5,624$2.09$12k137,803Nov 4, 2024
Oct 31, 2024David Roth
Chief Medical Officer
FTax withholding
Common Stock10b5-1
-6,776$2.09$14k12,099Nov 4, 2024
Oct 31, 2024Conley Chee
President & CEO
FTax withholding
Common Stock10b5-1
-8,707$2.09$18k130,797Nov 4, 2024
Oct 31, 2024Nancy A Simonian
director
MOption exercise
Restricted Stock Unitsderivative
-40,125$0.00$00Nov 4, 2024
Oct 31, 2024Kristin Stephens
Chief Development Officer
FTax withholding
Common Stock10b5-1
-6,104$2.09$13k36,133Nov 4, 2024
Oct 31, 2024Jason Haas
Chief Financial Officer
MOption exercise
Restricted Stock Unitsderivative10b5-1
-18,875$0.00$00Nov 4, 2024
Oct 31, 2024Conley Chee
President & CEO
MOption exercise
Restricted Stock Unitsderivative10b5-1
-17,000$0.00$00Nov 4, 2024
Oct 31, 2024David Roth
Chief Medical Officer
MOption exercise
Restricted Stock Unitsderivative10b5-1
-18,875$0.00$00Nov 4, 2024
Oct 31, 2024Kristin Stephens
Chief Development Officer
MOption exercise
Restricted Stock Unitsderivative10b5-1
-17,000$0.00$00Nov 4, 2024

Insiders

Everyone who has filed a Form 4 here.

Questions about SYRS

Answered from the filings on this page, as of the latest one.

Are insiders buying SYRS?

No. In the last 90 days no insider at Syros Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade SYRS on the open market?

Nancy A Simonian (director) sold $10k of SYRS on Dec 2, 2024 and filed the Form 4 on Dec 4, 2024. InsiderTell scored 50 (moderate), with 6 insiders on the same side within 14 days.

How many insiders file Form 4 at Syros Pharmaceuticals, Inc.?

6 people have filed a Form 4 at Syros Pharmaceuticals, Inc., among them Conley Chee (President & CEO), Jason Haas (Chief Financial Officer), Gerald E Quirk (Chief Legal & Compliance Offic). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

SYRS insider trading: Syros Pharmaceuticals, Inc. | InsiderTell